Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of Therapy

TLDR

Advances in diagnostic imaging, such as CT, MRI, and ultrasonography, have revolutionized medicine by enabling detailed whole‑body imaging and early detection of abnormalities, yet they also risk creating confusion that may harm patients. The study uses prostate cancer as a case to illustrate how these imaging advances can lead to overestimation of disease prevalence and affect therapeutic decisions.

Abstract

Over the past two decades a vast new armamentarium of diagnostic techniques has revolutionized the practice of medicine. The entire human body can now be imaged in exquisite anatomical detail. Computed tomography (CT), magnetic resonance imaging (MRI), and ultrasonography routinely “section” patients into slices less than a centimeter thick. Abnormalities can be detected well before they produce any clinical signs or symptoms. Undoubtedly, these technological advances have enhanced the physician's potential for understanding disease and treating patients. Unfortunately, these technological advances also create confusion that may ultimately be harmful to patients. Consider the case of prostate cancer. Although the prevalence . . .